Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
96 hedge funds and large institutions have $189M invested in Bellicum Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 46 increasing their positions, 13 reducing their positions, and 14 closing their positions.
254% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 13
56% more capital invested
Capital invested by funds: $121M → $189M (+$68M)
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
7% more funds holding
Funds holding: 90 → 96 (+6)
52% less call options, than puts
Call options by funds: $654K | Put options by funds: $1.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.6M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$8.2M |
| 3 |
BlackRock
New York
|
+$6.62M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.55M |
| 5 |
JP Morgan Chase
New York
|
+$5.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
-$2.63M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$2.3M |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$1.83M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.12M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$696K |
BLCM Hedge Fund Activity: Q2 2018 in Review
96 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2018, worth a combined $189M — up 56% from $121M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new BLCM positions and 14 closed out — a net gain of 6 holders — while 46 added to existing stakes and 13 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $15.6M. The largest seller was Ascend Capital, exiting entirely with an estimated $2.63M sold.
- 96 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2018, up from 90 in Q1 2018.
- Funds reported $189M of Bellicum Pharmaceuticals, Inc. stock for Q2 2018, up 56% quarter-over-quarter.
- 20 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2018 and 14 closed out, a net change of +6 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2018 was Farallon Capital Management, an estimated $15.6M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2018 was Ascend Capital, an estimated $2.63M sold.
Based on aggregated 13F filings for Q2 2018.